|
May 13
|
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
|
|
May 12
|
Applied DNA Sciences Second Quarter 2024 Earnings: Misses Expectations
|
|
May 10
|
Applied DNA Sciences (APDN) Reports Q2 Loss, Tops Revenue Estimates
|
|
May 10
|
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
|
|
May 10
|
‘Significant’ Volume of Xinjiang Cotton Mislabeled as US or Brazilian
|
|
May 10
|
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
May 9
|
Xinjiang cotton ‘widespread’ despite US UFLPA legislation
|
|
May 7
|
Banned Chinese cotton found in 19% of US and global retailers' merchandise, study shows
|
|
May 7
|
CORRECTED-Banned Chinese cotton found in 19% of US and global retailers' merchandise, study shows
|
|
Apr 25
|
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
|
|
Apr 22
|
Applied DNA Announces 1-For-20 Reverse Stock Split
|
|
Mar 18
|
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
|
|
Mar 14
|
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
|
|
Feb 8
|
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
|
|
Feb 8
|
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
|
|
Feb 5
|
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
|
|
Feb 2
|
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Dec 7
|
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
|
|
Dec 5
|
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
|
|
Nov 28
|
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
|